Lexicon Pharmaceuticals Inc

+0.08 (+4.97%)
Earnings Announcements

Lexicon Pharmaceuticals Reports Qtrly Loss Per Share $0.16

Published: 05/05/2022 11:31 GMT
Lexicon Pharmaceuticals Inc (LXRX) - Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update.
Qtrly Loss per Share $0.16.
Plan to Resubmit Our New Drug Application (nda) for Sotagliflozin for Treatment of Heart Failure This Month.
Q1 Earnings per Share View $-0.16 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0.05 Million
Adjusted EPS is expected to be -$0.15

Next Quarter Revenue Guidance is expected to be $0.05 Million
Next Quarter EPS Guidance is expected to be -$0.15

More details on our Analysts Page.